Even More Mergers and Acquisitions | Market Checkup - 4/28/14 | The Motley Fool

TL;DR

Onocogenics shares down due to drug trial failure, Forest Labs buying Fury X, Pfizer interested in AstraZeneca, Biogen's mixed earnings.

Transcript

hi fools welcome to market checkup the motley fools healthcare focused investing show i'm david williamson and i'm joined as usual by michael douglas how's it going michael you have a good weekend absolutely all right well let's get right to it we have a jam-packed show we have uh some more merger and acquisition news uh one that's happening one th... Read More

Key Insights

• 😀 Oncogenics faces a setback with their failed drug trial for prostate cancer, triggering a 50% share drop.
• ❓ Forest Labs' acquisition of Fury X bolsters their portfolio with an IBS drug and strategic drug sales, enhancing growth prospects.
• 👨‍💼 Pfizer's interest in AstraZeneca for a potential merger emphasizes tax benefits, overseas cash utilization, and portfolio alignment for improved business synergy.
• 🤨 Biogen reports mixed earnings but showcases revenue growth, raised guidance, and promising product pipeline for future growth.
• 🔬 Market volatility in healthcare investing demands vigilance and strategic decision-making for investors.
• 💪 Strong acquisitions and mergers indicate a dynamic landscape in healthcare investing with potential growth opportunities.
• 🚀 Success in drug trials and product launches can significantly impact stock performance and investor confidence.

Questions & Answers

Q: Why did Oncogenics shares drop by 50%?

Oncogenics faced a significant drop due to their drug trial for prostate cancer missing statistical significance and showing only marginal improvement in overall survival.

Q: What are the details of Forest Labs' acquisition of Fury X?

Forest Labs bought Fury X for over 20 billion, gaining an IBS drug and selling off two other drugs for 415 million to Royalty Pharma, enabling a strong product portfolio.

Q: What potential benefits does Pfizer see in acquiring AstraZeneca?

Pfizer eyes tax benefits from UK domiciling, utilization of overseas cash, and alignment with its structured three-division layout for a synergistic business merger.

Q: How did Biogen's earnings report fare and what are the future prospects?

Biogen reported mixed earnings with strong revenue growth and raised guidance, fueled by successful Tecfidera sales and an optimistic pipeline forecast for potential growth.

Summary & Key Takeaways

• Oncogenics faces a 50% drop due to a failed drug trial for prostate cancer.

• Forest Labs acquires Fury X, gaining an IBS drug & selling others for 415 million.

• Pfizer eyes AstraZeneca for a potential merger, Biogen reports mixed earnings with strong product potential.